Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported Q3 2026 results with a net loss of $26.4 million and cash, cash equivalents, and investments of $403.8 million as of September 30, 2026. Clinically, the company announced positive Phase 1 driving-simulation data for GlyphAllo, which did not impair next-morning driving performance, dosed the first patient in the GlyphAgo Phase 2a GAD trial, and kept BUOY-1 Phase 2b MDD enrollment on track with topline data expected 1H 2027.
Key figures
- Guidance
- Cash runway into 2029 through three mid-to-late-stage data readouts
- Net loss q3 2025
- 22500000
- Net loss q3 2026
- 26400000
- Ga expense q3 2025
- 5000000
- Ga expense q3 2026
- 6500000
- Rd expense q3 2025
- 20500000
- Rd expense q3 2026
- 23900000
- Cash and investments
- 403800000
- Weighted avg shares q3 2026
- 53530550
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.